BACKGROUND: The multicomponent serogroup B meningococcal (4CMenB) vaccine was recently licensed for use in Europe. There are currently no data on the persistence of bactericidal antibodies induced by use of this vaccine in infants. Our objective was to evaluate serogroup B-specific bactericidal antibodies in children aged 40-44 months previously vaccinated at 2, 4, 6 and 12 months of age. METHODS: Participants given 4 doses of 4CMenB as infants received a fifth dose of the vaccine at 40-44 months of age. Age-matched participants who were MenB vaccine-naive received 4CMenB and formed the control group. We evaluated human complement serum bactericidal activity (hSBA) titres at baseline and 1 month after each dose of 4CMenB. RESULTS: Before a booster dose at enrolment, 41%-76% of 17 participants previously vaccinated with 4CMenB in infancy had hSBA titres of 4 or greater against 4 reference strains. Before vaccination in the control group (n = 40) these proportions were similar for strains 44/76-SL (63%) and M10713 (68%) but low for strains NZ98/254 (0%) and 5/99 (3%). A booster dose in the 4CMenB-primed participants generated greater increases in hSBA titres than in controls. INTERPRETATION: As has been observed with other meningococcal vaccines, bactericidal antibodies waned after vaccination with 4CMenB administered according to an approved infant vaccination schedule of 2, 4, 6 and 12 months of age, but there was an anamnestic response to a booster dose at 40-44 months of age. If 4CMenB were introduced into routine vaccination schedules, assessment of the need for a booster dose would require data on the impact of these declining titres on vaccine effectiveness. ClinicalTrials.gov, no. NCT01027351.
RCT Entities:
BACKGROUND: The multicomponent serogroup B meningococcal (4CMenB) vaccine was recently licensed for use in Europe. There are currently no data on the persistence of bactericidal antibodies induced by use of this vaccine in infants. Our objective was to evaluate serogroup B-specific bactericidal antibodies in children aged 40-44 months previously vaccinated at 2, 4, 6 and 12 months of age. METHODS:Participants given 4 doses of 4CMenB as infants received a fifth dose of the vaccine at 40-44 months of age. Age-matched participants who were MenB vaccine-naive received 4CMenB and formed the control group. We evaluated human complement serum bactericidal activity (hSBA) titres at baseline and 1 month after each dose of 4CMenB. RESULTS: Before a booster dose at enrolment, 41%-76% of 17 participants previously vaccinated with 4CMenB in infancy had hSBA titres of 4 or greater against 4 reference strains. Before vaccination in the control group (n = 40) these proportions were similar for strains 44/76-SL (63%) and M10713 (68%) but low for strains NZ98/254 (0%) and 5/99 (3%). A booster dose in the 4CMenB-primed participants generated greater increases in hSBA titres than in controls. INTERPRETATION: As has been observed with other meningococcal vaccines, bactericidal antibodies waned after vaccination with 4CMenB administered according to an approved infant vaccination schedule of 2, 4, 6 and 12 months of age, but there was an anamnestic response to a booster dose at 40-44 months of age. If 4CMenB were introduced into routine vaccination schedules, assessment of the need for a booster dose would require data on the impact of these declining titres on vaccine effectiveness. ClinicalTrials.gov, no. NCT01027351.
Authors: Nicoletta Gossger; Matthew D Snape; Ly-Mee Yu; Adam Finn; Gianni Bona; Susanna Esposito; Nicola Principi; Javier Diez-Domingo; Etienne Sokal; Birgitta Becker; Dorothee Kieninger; Roman Prymula; Peter Dull; Ellen Ypma; Daniela Toneatto; Alan Kimura; Andrew J Pollard Journal: JAMA Date: 2012-02-08 Impact factor: 56.272
Authors: María Elena Santolaya; Miguel L O'Ryan; María Teresa Valenzuela; Valeria Prado; Rodrigo Vergara; Alma Muñoz; Daniela Toneatto; Gabriela Graña; Huajun Wang; Ralf Clemens; Peter M Dull Journal: Lancet Date: 2012-01-18 Impact factor: 79.321
Authors: Matthew D Snape; Tom Dawson; Philipp Oster; Anita Evans; Tessa M John; Brigitte Ohene-Kena; Jamie Findlow; Ly-Mee Yu; Ray Borrow; Ellen Ypma; Daniela Toneatto; Andrew J Pollard Journal: Pediatr Infect Dis J Date: 2010-11 Impact factor: 2.129
Authors: John Donnelly; Duccio Medini; Giuseppe Boccadifuoco; Alessia Biolchi; Joel Ward; Carl Frasch; E Richard Moxon; Maria Stella; Maurizio Comanducci; Stefania Bambini; Alessandro Muzzi; William Andrews; Jie Chen; George Santos; Laura Santini; Philip Boucher; Davide Serruto; Mariagrazia Pizza; Rino Rappuoli; Marzia Monica Giuliani Journal: Proc Natl Acad Sci U S A Date: 2010-10-20 Impact factor: 11.205
Authors: Jamie Findlow; Ray Borrow; Matthew D Snape; Tom Dawson; Ann Holland; Tessa M John; Anita Evans; Karen L Telford; Ellen Ypma; Daniela Toneatto; Philipp Oster; Elizabeth Miller; Andrew J Pollard Journal: Clin Infect Dis Date: 2010-10-18 Impact factor: 9.079
Authors: Timo Vesikari; Susanna Esposito; Roman Prymula; Ellen Ypma; Igor Kohl; Daniela Toneatto; Peter Dull; Alan Kimura Journal: Lancet Date: 2013-03-09 Impact factor: 79.321
Authors: Julie A Bettinger; David W Scheifele; Scott A Halperin; Wendy Vaudry; Jamie Findlow; Ray Borrow; Duccio Medini; Raymond Tsang Journal: Vaccine Date: 2013-04-12 Impact factor: 3.641
Authors: Manish Sadarangani; Tim Sell; Mildred A Iro; Matthew D Snape; Merryn Voysey; Adam Finn; Paul T Heath; Gianni Bona; Susanna Esposito; Javier Diez-Domingo; Roman Prymula; Adefowope Odueyungbo; Daniela Toneatto; Andrew J Pollard Journal: CMAJ Date: 2017-10-16 Impact factor: 8.262
Authors: Fiona McQuaid; Matthew D Snape; Tessa M John; Sarah Kelly; Hannah Robinson; Ly-Mee Yu; Daniela Toneatto; Diego D'Agostino; Peter M Dull; Andrew J Pollard Journal: CMAJ Date: 2015-03-23 Impact factor: 8.262
Authors: A R Giuliani; A Mattei; A Appetiti; D Pompei; F Di Donna; F Fiasca; L Fabiani Journal: Hum Vaccin Immunother Date: 2018-06-21 Impact factor: 3.452
Authors: Irene Rivero-Calle; Peter Francis Raguindin; Jose Gómez-Rial; Carmen Rodriguez-Tenreiro; Federico Martinón-Torres Journal: Infect Drug Resist Date: 2019-10-09 Impact factor: 4.003
Authors: Daniel O'Connor; Marta Valente Pinto; Dylan Sheerin; Adriana Tomic; Ruth E Drury; Samuel Channon-Wells; Ushma Galal; Christina Dold; Hannah Robinson; Simon Kerridge; Emma Plested; Harri Hughes; Lisa Stockdale; Manish Sadarangani; Matthew D Snape; Christine S Rollier; Michael Levin; Andrew J Pollard Journal: Mol Syst Biol Date: 2020-11 Impact factor: 11.429